Jaguar Health announced that the country of Jordan’s Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals for methods for treating short bowel syndrome, bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar’s novel plant-based prescription drug.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health’s Napo Pharmaceuticals issues Hong Kong patent for SBS treatment
- Jaguar Health reports Q2 EPS ($4.04) vs. ($41.35) last year
- Jaguar Health to explore approval pathway for crofelemer based on Phase 3 result
- Jaguar Health announces results of investigator-initiated studies of crofelemer
- Biotech Alert: Searches spiking for these stocks today